It's been a brutal week for the most shameless company in the opioid crisis - and it's about to get worse

Advertisement

Insys Jonathan Roper, Fernando Serrano

Reuters

Jonathan Roper (2nd L), a former Insys Therapeutics Inc district sales manager, and Fernando Serrano (C), a former sales representative at the company walk with Serrano's lawyer, Jude Cardenas (R), out of federal court after they pleaded not guilty to engaged in a scheme to pay doctors kickbacks to prescribe a fentanyl-based drug the company sells, in Manhattan, New York, U.S., August 17, 2016.

Key employees at Insys Therapeutics, the maker of powerful opioid Subsys, pled guilty to violating anti-kickback laws Tuesday and Wednesday.

Advertisement

It's part of an ongoing investigation that illustrates how Insys became the poster child for the evils of the opioid crisis and how some companies stopped at nothing to addict America.

The two employees are former sales reps Natalie Levine and Karen Hill. Levine, who is married to Insys' former CEO Michel Babich, pled guilty in Connecticut on Tuesday, and Hill pled guilty in Alabama on Wednesday. Both women face up to five years in prison. The company's stock is down around 5% on the news.

Levine admitted to paying off medical practitioners in order to get them to prescribe Subsys under the guise of a legal speakers program. The program, however, was a total scam.

From the Justice Department:

Advertisement

The Speaker Programs, which were typically held at high-end restaurants, were ostensibly designed to gather licensed healthcare professionals who had the capacity to prescribe Subsys and educate them about the drug. In truth, the events were usually just a gathering of friends and co-workers, most of whom did not have the ability to prescribe Subsys, and no educational component took place. "Speakers" were paid a fee that ranged from $1,000 to several thousand dollars for attending these dinners. At times, the sign-in sheets for the Speaker Programs were forged so as to make it appear that the programs had an appropriate audience of healthcare professionals.

Hill pleaded guilty to participating in the same sham speaker's program which helped to facilitate a $40 million opioid "pill mill" in Mobile, Alabama. That "pill mill" was a medical practice belonging to Dr. Xiulu Ruan and Dr. John Patrick Couch that overprescribed medication and engaged in insurance fraud. Both doctors have been sentenced to 20 and 21 years in prison respectively.

In June Elizabeth Gurrieri, a former manager of reimbursement services for Insys, pled guilty to wire fraud and conspiracy.

Former Insys Therapeutics Inc employee Elizabeth Gurrieri (R) leaves the federal court with members of her legal team in Boston, Massachusetts, U.S. on June 19, 2017.  REUTERS/Nate Raymond

Thomson Reuters

Former Insys Therapeutics Inc employee Elizabeth Gurrieri leaves the federal court in Boston

Things will likely get worse for Insys and other opioid-makers as the week goes on. According to Bloomberg, Attorney General Jeff Sessions is set to announce more measures to crackdown on fraudulent opioid insurance claims, as well as on fraud in opioid treatment centers, later this week. Hundreds of arrests will be carried out in cities around the country.

Advertisement

Federal prosecutors in Boston announced charges against half a dozen Insys executives back in December after years of reported shocking behavior. Investigative journalist Roddy Boyd at the Southern Investigative Reporting Foundation (SIRF) has done fascinating work highlighting it.

In 2015, he reported that Sunrise Lee, Insys' former central and later western sales region head, had no pharmaceutical sales experience before joining the company. Her previous employer was Rachel's, a West Palm Beach strip club where she was a dancer.

"Doctors really enjoyed spending time with her and found Sunrise to be a great listener," Insys' national sales chief Alex Burlakoff told SIRF.

"She's more of a 'closer,'" he continued. "Often the initial contact [with a doctor] was made by another salesperson."

NOW WATCH: The CEO of Mondelēz doesn't seem interested in buying Nestlé's candy business